CD79A and COVID-19: Perri et al. found that ocular anti-SARS-CoV-2 IgAs were detected in 10 out of 28 enrolled COVID-19 patients, and that high IgA positivity was observed as early as 2 days after nasopharyngeal/oropharyngeal swabs [23].